Strides Arcolab Ltd. announced that it has received approval from the US FDA for Buspirone Hydrochloride tablets USP, 5 mg, 10 mg, 15 mg and 30 mg.
Buspirone tablets are used for the treatment of anxiety disorders and the short-term relief of the symptoms of anxiety.
The company said the product would be manufactured at its Oral dosage facility at Bangalore and marketed directly by Strides in the US market.
As per IMS data as on September 2013, the US market for generic Buspirone tablets was around $65 million.
At the BSE, Strides Arcolab closed Tuesday's trading at Rs.657.05, down 1.93 percent from the previous day's close.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.